WHO and Novartis Pharma AG have negotiated an agreement whereby Novartis donates triclabendazole for the treatment of fascioliasis in endemic countries. The medicine is shipped free of charge to countries upon application from ministries of health. Small quantities can also be made available to other institutions in endemic countries for compassionate clinical use. WHO is responsible for collecting applications in all cases. A number of countries, including Bolivia (Plurinational State of), Georgia, Madagascar Peru, Viet Nam, Yemen, are receiving donated triclabendazole through this agreement.

Since 2010 triclabendazole is also donated for treating human paragonimiasis. If you need drugs to treat individuals infected with paragonimus spp. Please follow the same application process as above.

The recommended treatment regimen for paragonimiasis is triclabendazole, 20 mg/kg of body weight, in two divided doses of 10 mg/kg of body weight, to be administered on the same day.

In communities and villages where cases of paragonimiasis appear to be significantly clustered, universal treatment (MDA) should also be considered. In this case, the recommended treatment regimen would be triclabendazole, 20 mg/kg of body weight in a single administration.